Relmada Therapeutics, Inc. · NASDAQ:RLMD

Relmada Therapeutics — Technical Presentation (February 2022)

9 slides from Relmada Therapeutics's technical presentation, Feb 23, 2022

1. Slide 1: Human Abuse Potential (HAP) Study of REL-1017 vs. Ketamine

   Human Abuse Potential (HAP) Study of REL - 1017 vs. Ketamine February 23, 2022 I Nasdaq: RLMD 1

2. Slide 2: Disclosures

   Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward - lookin g statements.” These statem

3. Slide 3: Top-Line Results Conference Call & Webcast Agenda

   Human Abuse Potential (HAP) Study of REL - 1017 vs Ketamine Introduction Sergio Traversa, Chief Executive Officer of Relmada Study Design & Top - Line Results Jack Henningfield , Ph.D., Vice President, Research, Health Policy, and Abuse Liability at Pinney Associates; former Chief of the Clinical Ph

4. Slide 4: Human Abuse Potential (HAP) Study of IV Ketamine Summary

   Human Abuse Potential (HAP) Study of REL - 1017 vs. IV Ketamine Summary • All REL - 1017 doses, including 150 mg (6x therapeutic dose and MTD), were statistically different from IV ketamine 0.5 mg/Kg (p<0.05) • All REL - 1017 doses including, 150 mg (6x therapeutic dose and MTD), were statistically

5. Slide 5: Primary Endpoint – Drug Liking at This Moment [Emax] IV Ketamine, Completer Population

   Primary Endpoint – “Drug Liking at This Moment” [Emax] REL - 1017 vs. IV Ketamine, Completer Population Statistic Parameter Placebo REL - 1017 25 mg REL - 1017 75 mg REL - 1017 150 mg Ketamine 0.5 mg/Kg n 51 51 51 51 51 Mean 50.9 51.4 54.9 59.2 90 Median 50 50 50 51 100 VAS = Visual Analogue Scale;

6. Slide 6: Primary Endpoint – Maximum Drug Liking at This Moment [Emax] Statistical Analysis

   Primary Endpoint – “Maximum Drug Liking at This Moment” [Emax] REL - 1017 vs. IV Ketamine, Completer Population Treatment 1 Treatment 2 P - value Ketamine 0.5 mg/ Kg Placebo <0.05 Ketamine 0.5 mg/ Kg REL - 1017 25 mg <0.05 Ketamine 0.5 mg/ Kg REL - 1017 75 mg <0.05 Ketamine 0.5 mg/ Kg REL - 1017 150

7. Slide 7: US DEA July 2019 Statement on esmethadone

   US DEA July 2019 Statement on esmethadone 7 “The d - isomer lacks significant respiratory depressant action and addiction liability.. .” - DEA Statement July 2019 1 1.US DEA Statement on Methadone 2019 https:// www.deadiversion.usdoj.gov / drug_chem_info /methadone/ methadone.pdf#search =methadone

8. Slide 8: 6S

   3 6S 6

9. Slide 9: Thank You

   Relmada THERAPEUTICS Thank You

Relmada Therapeutics — Technical Presentation (February 2022) on 6ix